EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension study

Jerry Vockley iD, Barbara K Burton, Gerard Berry, Nicola Longo, John Phillips, Amarilis Sanchez-Valle, Kimberly A Chapman, Pranoot Tanpaiboon, Stephanie Grunewald, Elaine Murphy, Xiaoxiao Lu, Syeda Rahman und 4 weitere

Journal of Inherited Metabolic Disease · 2023

DOI: 10.1002/jimd.12640 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von Jerry Vockley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic and Genomic Medicine, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Lipid Metabolism, Inborn Errors. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Ultragenyx Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐chain fatty acid oxidation disorders (LC‐FAODs) result in life‐threatening energy metabolism deficiencies/energy source depletion. Triheptanoin is an odd‐carbon, medium chain triglyceride (that is an anaplerotic substrate of calories and fatty acids) for treating pediatric and adult patients with LC‐FAODs. Study CL202 (NCT02214160), an open‐label extension study of study CL201 (NCT01886378), evaluated the long‐term safety/efficacy of triheptanoin in patients with LC‐FAODs ( N = 94), including cohorts who were triheptanoin naïve ( n = 33) or had received triheptanoin in study CL201 ( n = 24) or in investigator‐sponsored trials/expanded access programs (IST/EAPs; n = 37). Primary endpoint was the annualized rate of LC‐FAOD major clinical events (MCEs; rhabdomyolysis, hypoglycemia, cardiomyopathy). Mean ± standard deviation (SD) triheptanoin treatment durations were 27.4 ± 19.9, 46.9 ± 13.6, and 49.6 ± 21.4 months for the triheptanoin‐naïve, CL201 rollover, and IST/EAP cohorts, respectively. In the triheptanoin‐naïve cohort, median (interquartile range [IQR]) MCE rate significantly decreased from 2.00 (0.67–3.33) events/patient/year pre‐triheptanoin to 0.28 (0.00–1.43) events/patient/year with triheptanoin ( p = 0.0343), a reduction of 86%. In the CL201 rollover cohort, mean ± SD MCE rate significantly decreased from 1.76 ± 1.64 events/patient/year pre‐triheptanoin to 1.00 ± 1.00 events/patient/year with triheptanoin ( p = 0.0347), a reduction of 43%. In the IST/EAP cohort, mean ± SD MCE rate was 1.40 ± 2.37 (median [IQR] 0.57 [0.00–1.67]) events/patient/year with triheptanoin. Safety data were consistent with previous observations. Treatment‐related treatment‐emergent adverse events (TEAEs) occurred in 68.1% of patients and were mostly mild/moderate in severity. Five patients had seven serious treatment‐related TEAEs; all resolved. Our results confirm the long‐term efficacy of triheptanoin for patients with LC‐FAOD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipid Metabolism, Inborn ErrorsAdultChildHumansFatty AcidsOxidation-ReductionTriglycerides

Stichwörter der Autor:innen

cardiomyopathyhypoglycemialong-chain fatty acid oxidation disordersrhabdomyolysistriheptanoin (Dojolvi®)

Substanzen

Fatty AcidsTriglyceridestriheptanoin

Autor:innen und Institutionen

  • Division of Genetic and Genomic Medicine, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
  • Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pediatrics, University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.

ORCID-Profile: Jerry Vockley

Förderung

  • NIDDK NIH HHS
  • Ultragenyx Pharmaceutical

Zitieren

APA

Vockley, J., Burton, B. K., Berry, G., Longo, N., Phillips, J., Sanchez-Valle, A., Chapman, K. A., Tanpaiboon, P., Grunewald, S., Murphy, E., Lu, X., Rahman, S., Ray, K., Reineking, B., Pisani, L., & Ramirez, A. N. (2023). Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension study. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12640

Vancouver

Vockley J, Burton BK, Berry G, Longo N, Phillips J, Sanchez-Valle A, et al. Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension study. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12640

BibTeX
@article{Vockley2023,
  author = {Vockley, Jerry and Burton, Barbara K and Berry, Gerard and Longo, Nicola and Phillips, John and Sanchez-Valle, Amarilis and Chapman, Kimberly A and Tanpaiboon, Pranoot and Grunewald, Stephanie and Murphy, Elaine and Lu, Xiaoxiao and Rahman, Syeda and Ray, Kathryn and Reineking, Bridget and Pisani, Laura and Ramirez, Antonio Nino},
  title = {Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension study},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  doi = {10.1002/jimd.12640}
}
Kostenlos starten →